|
Aug 12
|
ALK upgrades its full-year revenue outlook
|
|
Aug 12
|
Peanut Allergy Treatment Market Report 2025-2033, with Key Player Profiles for Aimmune Therapeutics, DBV Technologies, Sanofi, ALK-Abello, Prota Therapeutics, Camallergy, Aravax, and Genentech
|
|
Jul 21
|
ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system
|
|
Jul 18
|
MHRA approves needle-free adrenaline nasal spray for anaphylaxis
|
|
Jul 18
|
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
|
|
Jul 18
|
EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
|
|
Jun 26
|
First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany
|
|
May 2
|
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
|
|
May 2
|
ALK enters into neffy® co-promotion agreement in the USA
|
|
Apr 29
|
Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025
|
|
Jan 22
|
3 Stocks Estimated To Be Trading At Discounts Of 26% To 44%
|